Apreo Health offers the Apreo BREATHE Airway Scaffold, a bronchoscopic, self‑expanding nitinol device that tents open targeted airways to release trapped air and reduce hyperinflation in patients with severe emphysema. The minimally invasive, low‑profile scaffold can be placed via standard bronchoscopy in both lungs, aiming to improve lung function, lessen breathlessness, and expand eligibility for airway‑support treatments.
Funding
$130M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
4OBCNVFounders
Product
Problem
Patients with severe emphysema experience chronic hyperinflation as damaged air sacs trap air, leading to persistent shortness of breath and reduced quality of life. Existing treatments often involve invasive surgery or provide limited relief, leaving many patients without effective options to improve lung function.
Solution
Apreo Health has developed the Apreo BREATHE Airway Scaffold, a bronchoscopic, self‑expanding nitinol device that tents open targeted airways to release trapped air and reduce hyperinflation. The minimally invasive procedure delivers a low‑profile scaffold that supports airway patency while preserving side branches, aiming to improve breathing capacity and lessen breathlessness. By integrating the scaffold via a standard bronchoscope, the treatment can be performed in both lungs with a streamlined workflow, potentially expanding eligibility to a broader patient population. Clinical studies (BREATHE 1&2) are evaluating safety and functional outcomes, with early data indicating improvements in lung mechanics and patient‑reported quality of life.
Target Audience
The primary customers are pulmonologists and thoracic surgeons treating patients with severe emphysema who are candidates for minimally invasive airway interventions.
Features
- Self‑expanding nitinol scaffold designed for bronchoscopic delivery and precise airway tenting
- Flexible, low‑profile architecture to minimize foreign body reaction and maintain side‑branch flow
- Intended for use in both lungs, supporting broader patient eligibility
- Procedure integrates into existing bronchoscopy suites, reducing the need for additional equipment
- Investigational device currently evaluated in first‑in‑human feasibility trials (BREATHE 1&2)